查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1470838

疫苗市场：按类型、技术类型、适应症、给药途径、年龄组划分 - 2024-2030 年全球预测

Vaccines Market by Type (Monovalent Vaccine, Multivalent Vaccine), Technology Type (Inactivated Vaccines, Live-Attenuated Vaccines, Messenger RNA (mRNA) Vaccines), Indication, Route of administration, Age Group - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计2023年疫苗市场规模为556.6亿美元，预计2024年将达到599.4亿美元，2030年将达到941.4亿美元，复合年增长率为7.79%。

疫苗是生物製药，使人体免疫系统能有效对抗致病微生物。它的作用是刺激免疫反应并建立针对有害病原体的特异性防御机制（主要以抗体的形式）。全球感染疾病率上升和全球免疫计划的增加是这一增长的主要原因。此外，政府在疫苗研发方面的积极努力和政策也是市场开拓的动力。高昂的开发成本、漫长的测试和核准流程、产品召回问题以及部分地区的供应困难等给疫苗市场的成长带来了挑战。佐剂在疫苗中的整合、治疗性疫苗的开发以及疫苗契约製造的成长预计将为市场提供重大的成长机会。

主要市场统计
基准年[2023] 556.6亿美元
预测年份 [2024] 599.4亿美元
预测年份 [2030] 941.4亿美元
复合年增长率（%） 7.79%

类型：更偏好旨在预防特定疾病的单价疫苗

单价疫苗针对一种抗原或微生物，产生强烈、集中的免疫反应。例如，麻疹疫苗通常以 MMR II 的形式施用，这是一种在世界各地广泛普及的单价疫苗。当单一疾病占主导地位并且需要特异性的免疫反应时，此类疫苗是理想的选择。多效价疫苗可刺激针对多种病原体或相同病原体菌株的免疫力。一种广泛普及的多效价疫苗是 DTP 疫苗，可预防白喉、破伤风和百日咳。多效价疫苗非常适合多种疾病同时发生的环境。单价疫苗可以更好地对抗特定疾病，多效价疫苗可以提供广泛的保护，但这两种类型对于满足世界疾病预防需求都至关重要。製造多效价疫苗需要更复杂的过程，以确保对多种病原体的功效。然而，从公共卫生的角度来看，其广泛的适用性可能物有所值。

技术类型：结合疫苗的开发正在进行中。

灭活疫苗通常是给免疫力缺乏的人开的，是透过中和病原体来生产的。由减毒活病毒开发的减毒活疫苗描述了适合强大免疫系统的长期免疫力。传讯RNA(mRNA) 疫苗是一种新型疫苗，它使用病毒 RNA 的某些副本来触发免疫反应。次单元、重组体、多醣体和结合物是由病原体的部分成分製成的，可供对某些疫苗成分过敏的人使用。类毒素疫苗旨在预防细菌产生的毒素，并提供给易受此类感染疾病的人。病毒载体疫苗的病毒表面含有编码蛋白质的 DNA，可刺激免疫反应。这些疫苗中的每一种都在预防感染疾病方面发挥着重要作用。选择主要根据患者的年龄、免疫状态和过敏倾向。新的开发、合作和发布正在丰富这一领域，并提供更好的患者照护选择。

适应症：针对严重呼吸道疾病的百白破疫苗需求不断增加

DPT 疫苗用于预防白喉、百日咳和破伤风。通常，2个月、4个月、6个月、15至18个月和4至6岁的婴幼儿会接种五剂系列疫苗以进行免疫。肝炎疫苗（包括甲型肝炎和B型肝炎）用于预防这些病毒的感染，这些病毒主要影响肝臟。两种疫苗通常分两剂接种，第二剂疫苗在第一剂接种后 6 个月接种。人类乳突病毒 (HPV) 疫苗用于预防已知会导致某些癌症（例如子宫颈癌和喉癌）的病毒感染。通常为 9 至 14 岁的青春期前儿童分两次接种，间隔 6 个月。流感疫苗通常称为“流感疫苗”，每年註射一次以预防季节性流感病毒。建议 6 个月及以上的所有人，尤其是那些有严重流感併发症风险的人，例如老年人和患有慢性疾病的人。麻疹疫苗通常作为麻疹-腮腺炎-德国麻疹(MMR) 疫苗的一部分接种，为 12 至 15 个月和 4 至 6 岁的儿童接种，以预防这些高度传染性的病毒性疾病。脑膜炎双球菌疫苗用于预防可能导致脑膜炎和血液感染等严重症状的细菌感染。脑膜炎双球菌疫苗用于预防可能导致脑膜炎和血液感染等严重症状的细菌感染。流行性腮腺炎和德国德国麻疹疫苗通常是作为 MMR 疫苗和麻疹疫苗的一部分接种。儿童注射两剂以确保免疫力。然而，即使是没有免疫力或没有疫苗接种史的成年人也可能需要接种疫苗。肺炎链球菌疫苗可预防引起肺炎、脑膜炎和血液感染等肺炎球菌疾病的细菌，适用于所有 2 岁以下儿童、65 岁以上成人以及患有某些健康状况的人。脊髓灰质炎疫苗用于预防脊髓灰质炎，这是一种导致瘫痪的高度传染性疾病。儿童通常分四剂接种：2 个月、4 个月、6 至 18 个月和 4 至 6 岁。轮状病毒疫苗可预防导致婴幼儿严重腹泻的病毒感染疾病。该疫苗通常在出生后的前 6 个月内口服 2 至 3 剂。接种水痘疫苗是为了预防传染性很强的水痘。疫苗通常分两剂接种，第一剂在 12 至 15 个月大时接种，第二剂在 4 至 6 岁时接种。

给药途径：越来越多地采用口服给药来延长免疫反应，以获得更持久的疫苗

最常见的疫苗接种方法是肌肉注射和皮下注射。这种给药途径使疫苗保持在肌肉内或皮下注射，促进有效的免疫反应。当不希望透过针头给药或不切实际时，通常使用口服给药。轮状病毒、脊髓灰质炎(OPV) 和霍乱的口服治疗已被证明是有效且易于管理的。两种给药途径均具有独特的优势，包括肌肉或皮下给药的快速免疫和口服给药的无针便利性。然而，每种疫苗都有缺点，例如肌肉注射和皮下注射会带来疼痛和针刺伤，以及口服疫苗会因胃肠道状况而受到限制。疫苗的选择取决于个人疫苗、接种者和医疗保健环境。对非侵入性疫苗接种方法的探索预计将促进产业研究和伙伴关係。

年龄层： 人类乳突病毒(HPV)疫苗效用的增加增加了儿童用疫苗作为预防措施的采用

18岁及以上的成年人口占据了疫苗市场的大部分。该群体主要需要疫苗来增强免疫力、预防疾病、满足旅游免疫需求。疫苗市场的儿童部分主要针对 18 岁以下的儿童。必要的免疫接种、疾病预防和遵守最高医疗建议是这一类别的主要动力。成人疫苗市场非常注重预防和维护，而儿童市场则主要注重预防。

区域洞察

在亚太地区，中国、印度和日本等强劲经济体的疫苗市场呈现显着成长，人口密度高、感染疾病爆发率高，需要全面免疫。由于人口结构和广泛的公共卫生基础设施，包括美国和加拿大在内的美洲对疫苗的需求很高。对疫苗研发（R＆D）的大量投资、最近的专利和倡议进一步支持了成长。欧洲、中东和非洲的经济格局不同，消费者行为也各不相同。欧盟（EU）拥有强大的医疗保健系统，需要大规模的疫苗接种计画。中东和非洲市场成长潜力大。印度血清研究所和非洲疫苗采购信託基金之间的 2022 年 COVID-19 供应合作等措施是塑造这一格局的关键变化。

FPNV定位矩阵

FPNV定位矩阵对于评估疫苗市场至关重要。我们检视与业务策略和产品满意度相关的关键指标，以对供应商进行全面评估。这种深入的分析使用户能够根据自己的要求做出明智的决策。根据评估，供应商被分为四个成功程度不同的像限。最前线 (F)、探路者 (P)、利基 (N) 和重要 (V)。

市场占有率分析

市场占有率分析是一种综合工具，可以对疫苗市场供应商的现状进行深入而深入的研究。全面比较和分析供应商在整体收益、基本客群和其他关键指标方面的贡献，以便更好地了解公司的绩效及其在争夺市场占有率时面临的挑战。此外，该分析也为此细分市场的竞争特征提供了宝贵的见解，包括在研究基准年观察到的累积、分散主导地位和合併特征等因素。这种详细程度的提高使供应商能够做出更明智的决策并制定有效的策略，从而在市场上获得竞争优势。

本报告在以下方面提供了宝贵的见解：

1. 市场渗透率：提供有关主要企业所服务的市场的全面资讯。

2. 市场开拓：我们深入研究利润丰厚的新兴市场，并分析其在成熟细分市场的渗透率。

3. 市场多元化：包括新产品发布、开拓地区、最新发展和投资的详细资讯。

4.竞争评估与资讯：对主要企业的市场占有率、策略、产品、认证、监管状况、专利状况、製造能力等进行全面评估。

5. 产品开发与创新：包括对未来技术、研发活动以及突破性产品开发的智力见解。

本报告解决了以下关键问题：

1.疫苗市场的市场规模和预测是多少？

2.疫苗市场预测期内我们应该考虑投资哪些产品与应用？

3. 疫苗市场的技术趋势和法规结构是什么？

4.疫苗市场主要厂商的市场占有率是多少？

5. 进入疫苗市场的适当形式和策略手段是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 全球感染疾病率正在上升
      • 疫苗开发的首选政府措施和政策
      • 世界各地对疫苗接种的兴趣增加
    • 抑制因素
      • 开发成本高、测试核准流程长
    • 机会
      • 佐剂在疫苗中的整合和治疗性疫苗的开发
      • 疫苗合约生产的成长
    • 任务
      • 部分地区出现产品召回及供货困难
  • 市场区隔分析
    • 类型：对特定疾病预防的单价疫苗有显着偏好
    • 技术类型：结合疫苗的不断发展作为可行的替代方案
    • 适应症：预防严重呼吸道疾病的百白破疫苗的需求不断增加
    • 给药途径：越来越多地采用口服给药，以更长时间维持免疫反应
    • 年龄层： 人类乳突病毒(HPV)疫苗的效用不断提高，促使儿童疫苗作为预防措施的采用率不断提高
  • 市场扰动分析
  • 波特五力分析
  • 价值炼和关键路径分析
  • 价格分析
  • 技术分析
  • 专利分析
  • 贸易分析
  • 法规结构分析

第六章疫苗市场：依类型

  • 介绍
  • 单价疫苗
  • 多效价疫苗

第七章疫苗市场：依技术类型

  • 介绍
  • 无效疫苗
  • 减毒活疫苗
  • 传讯RNA(mRNA) 疫苗
  • 次单元、重组、多醣体、结合疫苗
  • 类毒素疫苗
  • 病毒载体疫苗

第八章 疫苗市场：依适应症分类

  • 介绍
  • 二氧化硅
  • 肝炎
  • 人类乳突病毒
  • 流感
  • 麻疹
  • 病菌感染
  • 腮腺炎和德国麻疹
  • 肺炎链球菌感染
  • 脊髓灰质炎
  • 轮状病毒
  • 水痘

第九章疫苗市场：依给药途径

  • 介绍
  • 肌肉内和皮下
  • 口服

第10章疫苗市场：依年龄组

  • 介绍
  • 成人
  • 儿童

第十一章美洲疫苗市场

  • 介绍
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十二章亚太疫苗市场

  • 介绍
  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十三章欧洲、中东和非洲疫苗市场

  • 介绍
  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第14章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

第15章竞争产品组合

  • 主要企业简介
  • 主要产品系列
Product Code: MRR-434CCDA0513E

[194 Pages Report] The Vaccines Market size was estimated at USD 55.66 billion in 2023 and expected to reach USD 59.94 billion in 2024, at a CAGR 7.79% to reach USD 94.14 billion by 2030.

Vaccines are biological preparations that equip the body's immune system with the capability to combat disease-causing microbes effectively. They work by stimulating the immune response to generate a specific defense mechanism, predominantly in the form of antibodies, against harmful pathogens. The rising incidence of infectious diseases globally and the rise in immunization programs worldwide significantly influence this growth. Moreover, favorable government initiatives and policies for vaccine development are also driving market growth. High development costs, lengthy testing and approval process issues over product recalls, and inaccessibility in a few regions pose challenges to the growth of the vaccine market. Integration of adjuvants in vaccines, development of therapeutic vaccines, and growth in the contract manufacturing of the vaccines are expected to create significant growth opportunities in the market.

KEY MARKET STATISTICS
Base Year [2023] USD 55.66 billion
Estimated Year [2024] USD 59.94 billion
Forecast Year [2030] USD 94.14 billion
CAGR (%) 7.79%

Type: Significant preference for monovalent vaccines for specific disease prevention

Monovalent vaccines target one antigen or microorganism, producing a potent, focused immune response. For instance, the measles vaccine, commonly delivered in the M-M-R II format, is a globally prevalent monovalent vaccine. Such vaccines are ideal when single diseases dominate, requiring a specific immune response. Multivalent vaccines stimulate immunity against multiple pathogens or strains of the same pathogen. A widespread multivalent vaccine is the DTP vaccine, which safeguards against Diphtheria, Tetanus, and Pertussis. Multivalent vaccines are best suited for environments with multiple concurrent diseases. Even though monovalent vaccines excel in combating specific illnesses and multivalent vaccines offer broad-scope protection, both types are indispensable for addressing global disease prevention needs. Crafting multivalent vaccines requires a more intricate process to ensure efficacy against various pathogens. Nevertheless, their vast coverage could present superior, cost-effective advantages from a public health standpoint.

Technology Type: Rising development in the conjugate vaccines as an viable alternative

Inactivated vaccines, typically prescribed for the immune-compromised, are produced by neutralizing a pathogen. Live-attenuated vaccines, developed from a live yet weakened virus, provide prolonged immunity suitable for robust immune systems. Messenger RNA (mRNA) vaccines, a new breed of vaccines, use a copy of a part of the virus's RNA to provoke an immune response. Subunit, recombinant, polysaccharide, and conjugate vaccines are made from a piece of the pathogen that can be utilized by those allergic to certain vaccine components. Toxoid vaccines are designed to protect against bacteria-produced toxins, and are provided to individuals prone to such infections. Viral vector vaccines function by carrying a piece of DNA that codes for a protein found on the virus surface to stimulate an immune response. Each of these types of vaccines plays a crucial role in preventing infectious diseases. The selection depends mainly on the patient's age, immune status, or predisposed allergies. New developments, collaborations, and launches have further enriched this field, providing better patient care options.

Indication: Growing need for DPT vaccine for protection against serious respiratory ailments

The DPT vaccine is administered to protect against diphtheria, pertussis (whooping cough), and tetanus. It's typically given in a series of five shots to infants and toddlers at two months, four months, six months, 15-18 months, and 4-6 years of age to develop immunity. Hepatitis vaccines, including Hepatitis A and B, are administered to prevent these viral infections that primarily affect the liver. Both vaccines are usually given as two shots, with the second dose delivered six months after the first. The Human Papillomavirus (HPV) vaccine is given to protect against the viral infection known to cause certain types of cancers, such as cervical and throat cancer. It is usually given to preadolescents aged 9-14 over two doses six months apart. The influenza vaccine, typically known as the 'flu shot,' is given annually to protect against seasonal flu viruses. It's recommended for everyone over the age of 6 months, particularly those at risk of severe flu complications, such as the elderly and people with chronic health conditions/ The Measles vaccine is commonly given as part of the measles, mumps, and rubella (MMR) vaccine, and administered in a series of two doses at 12-15 months and 4-6 years of age to protect against these highly contagious viral diseases. The Meningococcal vaccine is given to protect against bacterial infections that can lead to severe conditions such as meningitis and bloodstream infections. It's usually administered to preteens and teenagers and includes a booster shot in the late teens. Mumps and Rubella vaccines are typically given as part of the MMR vaccine and measles. Two doses are given in childhood to ensure immunity. However, adults without immunity or vaccination records may also require vaccination. The Pneumococcal vaccine protects against types of bacteria that cause pneumococcal disease, including pneumonia, meningitis, and bloodstream infections, for all children under the age of 2, adults 65 years and above, and individuals with specific health conditions. The Polio vaccine is given to prevent poliomyelitis, a highly infectious disease that leads to paralysis. Children typically receive four doses at two months, four months, 6-18 months, and 4-6 years. The Rotavirus vaccine protects against a viral infection provoking severe diarrhea in infants and young children. It's typically given orally in two or three doses during the first six months of life. The Varicella vaccine is administered to protect against chickenpox, a highly contagious disease. It's typically given in two doses, with the first dose at 12-15 months and the second at 4-6 years of age.

Route of administration: Increasing adoption of oral vaccines for longer-lasting immune responses

Intramuscular and Subcutaneous administrations are the most common methods for vaccine delivery. This route allows the vaccine to be retained in the muscle or beneath the skin, promoting an efficient immune response. The oral route of vaccine administration is a popular alternative often used when needle-based administration is not preferred or practical. Oral vaccines, such as those for rotavirus, polio (OPV), and cholera, have proven effective and easy to administer. Both administration routes have unique advantages, such as swift immunity in intramuscular and subcutaneous administration and needle-free convenience with oral vaccines. However, they each have drawbacks, such as pain and needle-stick injuries from intramuscular and subcutaneous injections or restrictions due to gastrointestinal conditions for oral vaccines. Vaccine selection depends upon the individual vaccine, recipient, and healthcare environment. Advancements in non-intrusive vaccination methods are anticipated to drive industry research and partnerships.

Age Group: wider adoption of pediatric vaccine as a preventive measure owing to rising HPV vaccine usability

The adult population, considered those over the age of 18, comprises the more significant portion of the vaccine market. This group primarily requires vaccines to boost their immunity, prevent diseases, and meet the needs of travel vaccinations. The pediatric segment of the vaccine market focuses on children under the age of 18. Necessary immunizations, disease prevention, and peak medical advisory compliance primarily drive this category. While the adult vaccine market excels in prevention and maintenance, the pediatric section is fundamentally preventive.

Regional Insights

In Asia-Pacific, robust economies such as China, India, and Japan have exhibited significant growth in vaccine markets due to large population densities and high prevalence of infectious diseases, necessitating comprehensive immunization drives. There's a high need for vaccines in the Americas, comprising countries such as the United States and Canada, owing to the demographic makeup and an expansive public health infrastructure. Significant investments in research and development (R&D) of vaccines, recent patents, and initiatives further fuel the growth. The EMEA region, with diverse economic landscapes, displays varying consumer behavior. The European Union, with well-funded health systems, necessitates extensive immunization programs. The Middle East and Africa possess a significant potential for market growth. Initiatives such as the collaboration between the Serum Institute of India and the Africa Vaccine Acquisition Trust in 2022 to supply COVID-19 vaccines are pivotal changes reshaping this landscape.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Vaccines Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Vaccines Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Vaccines Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Astellas Pharma Inc., AstraZeneca PLC, Bavarian Nordic A/S, Bharat Biotech Ltd., Biological E. Limited, Chongqing Zhifei Biological Products Co.,Ltd., CSL Limited, CureVac SE, Daiichi Sankyo Co., Ltd., Emergent BioSolutions Inc., Gennova Biopharmaceuticals Limited, GlaxoSmithKline PLC, Inovio Pharmaceuticals, Inc., Johnson & Johnson Services, Inc., Merck KGaA, Mitsubishi Chemical Group Corporation, Moderna Inc., Novavax, Inc., Pfizer Inc., Sanofi Group, Serum Institute of India Pvt. Ltd., Sinovac Biotech Ltd., Takeda Pharmaceutical Company Limited, and Zydus Lifesciences Limited.

Market Segmentation & Coverage

This research report categorizes the Vaccines Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Type
    • Monovalent Vaccine
    • Multivalent Vaccine
  • Technology Type
    • Inactivated Vaccines
    • Live-Attenuated Vaccines
    • Messenger RNA (mRNA) Vaccines
    • Subunit, Recombinant, Polysaccharide, & Conjugate Vaccines
    • Toxoid Vaccines
    • Viral Vector Vaccines
  • Indication
    • DPT
    • Hepatitis
    • Human Papillomavirus
    • Influenza
    • Measles
    • Meningococcal Disease
    • Mumps & Rubella
    • Pneumococcal Disease
    • Polio
    • Rotavirus
    • Varicella
  • Route of administration
    • Intramuscular & Subcutaneous
    • Oral
  • Age Group
    • Adults
    • Pediatric
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Vaccines Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Vaccines Market?

3. What are the technology trends and regulatory frameworks in the Vaccines Market?

4. What is the market share of the leading vendors in the Vaccines Market?

5. Which modes and strategic moves are suitable for entering the Vaccines Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising incidence of infectious diseases globally
      • 5.1.1.2. Favorable government initiatives and policies for vaccine development
      • 5.1.1.3. Growing focus on immunization across the world
    • 5.1.2. Restraints
      • 5.1.2.1. High development costs, lengthy testing and approval processes
    • 5.1.3. Opportunities
      • 5.1.3.1. Integration of adjuvants in vaccines and development of therapeutic vaccines
      • 5.1.3.2. Growth in the contract manufacturing of the vaccines
    • 5.1.4. Challenges
      • 5.1.4.1. Issues over product recalls and inaccessibility in few regions
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Significant preference for monovalent vaccines for specific disease prevention
    • 5.2.2. Technology Type: Rising development in the conjugate vaccines as an viable alternative
    • 5.2.3. Indication: Growing need for DPT vaccine for protection against serious respiratory ailments
    • 5.2.4. Route of administration: Increasing adoption of oral vaccines for longer-lasting immune responses
    • 5.2.5. Age Group: wider adoption of pediatric vaccine as a preventive measure owing to rising HPV vaccine usability
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. Vaccines Market, by Type

  • 6.1. Introduction
  • 6.2. Monovalent Vaccine
  • 6.3. Multivalent Vaccine

7. Vaccines Market, by Technology Type

  • 7.1. Introduction
  • 7.2. Inactivated Vaccines
  • 7.3. Live-Attenuated Vaccines
  • 7.4. Messenger RNA (mRNA) Vaccines
  • 7.5. Subunit, Recombinant, Polysaccharide, & Conjugate Vaccines
  • 7.6. Toxoid Vaccines
  • 7.7. Viral Vector Vaccines

8. Vaccines Market, by Indication

  • 8.1. Introduction
  • 8.2. DPT
  • 8.3. Hepatitis
  • 8.4. Human Papillomavirus
  • 8.5. Influenza
  • 8.6. Measles
  • 8.7. Meningococcal Disease
  • 8.8. Mumps & Rubella
  • 8.9. Pneumococcal Disease
  • 8.10. Polio
  • 8.11. Rotavirus
  • 8.12. Varicella

9. Vaccines Market, by Route of administration

  • 9.1. Introduction
  • 9.2. Intramuscular & Subcutaneous
  • 9.3. Oral

10. Vaccines Market, by Age Group

  • 10.1. Introduction
  • 10.2. Adults
  • 10.3. Pediatric

11. Americas Vaccines Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Vaccines Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Vaccines Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. Oxford R21/Matrix-M Malaria Vaccine Receives WHO Recommendation for Use
    • 14.3.2. BioNTech and CEPI Announce Partnership to Advance mRNA Mpox Vaccine Development and Support CEPI's 100 Days Mission
    • 14.3.3. Pfizer and BioNTech Receive U.S. FDA Approval for 2023-2024 COVID-19 Vaccine
  • 14.4. Strategy Analysis & Recommendation

15. Competitive Portfolio

  • 15.1. Key Company Profiles
  • 15.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. VACCINES MARKET RESEARCH PROCESS
  • FIGURE 2. VACCINES MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL VACCINES MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL VACCINES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. VACCINES MARKET DYNAMICS
  • FIGURE 7. GLOBAL VACCINES MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL VACCINES MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL VACCINES MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL VACCINES MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 14. GLOBAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. GLOBAL VACCINES MARKET SIZE, BY AGE GROUP, 2023 VS 2030 (%)
  • FIGURE 16. GLOBAL VACCINES MARKET SIZE, BY AGE GROUP, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. AMERICAS VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. AMERICAS VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. UNITED STATES VACCINES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 20. UNITED STATES VACCINES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. ASIA-PACIFIC VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. ASIA-PACIFIC VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 25. VACCINES MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 26. VACCINES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. VACCINES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL VACCINES MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL VACCINES MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL VACCINES MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL VACCINES MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL VACCINES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL VACCINES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL VACCINES MARKET SIZE, BY MONOVALENT VACCINE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL VACCINES MARKET SIZE, BY MONOVALENT VACCINE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL VACCINES MARKET SIZE, BY MULTIVALENT VACCINE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL VACCINES MARKET SIZE, BY MULTIVALENT VACCINE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL VACCINES MARKET SIZE, BY INACTIVATED VACCINES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL VACCINES MARKET SIZE, BY INACTIVATED VACCINES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL VACCINES MARKET SIZE, BY LIVE-ATTENUATED VACCINES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL VACCINES MARKET SIZE, BY LIVE-ATTENUATED VACCINES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL VACCINES MARKET SIZE, BY MESSENGER RNA (MRNA) VACCINES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL VACCINES MARKET SIZE, BY MESSENGER RNA (MRNA) VACCINES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL VACCINES MARKET SIZE, BY SUBUNIT, RECOMBINANT, POLYSACCHARIDE, & CONJUGATE VACCINES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL VACCINES MARKET SIZE, BY SUBUNIT, RECOMBINANT, POLYSACCHARIDE, & CONJUGATE VACCINES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL VACCINES MARKET SIZE, BY TOXOID VACCINES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL VACCINES MARKET SIZE, BY TOXOID VACCINES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL VACCINES MARKET SIZE, BY VIRAL VECTOR VACCINES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL VACCINES MARKET SIZE, BY VIRAL VECTOR VACCINES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL VACCINES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL VACCINES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL VACCINES MARKET SIZE, BY DPT, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL VACCINES MARKET SIZE, BY DPT, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL VACCINES MARKET SIZE, BY HEPATITIS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL VACCINES MARKET SIZE, BY HEPATITIS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL VACCINES MARKET SIZE, BY HUMAN PAPILLOMAVIRUS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL VACCINES MARKET SIZE, BY HUMAN PAPILLOMAVIRUS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL VACCINES MARKET SIZE, BY INFLUENZA, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL VACCINES MARKET SIZE, BY INFLUENZA, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL VACCINES MARKET SIZE, BY MEASLES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL VACCINES MARKET SIZE, BY MEASLES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL VACCINES MARKET SIZE, BY MENINGOCOCCAL DISEASE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL VACCINES MARKET SIZE, BY MENINGOCOCCAL DISEASE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 41. GLOBAL VACCINES MARKET SIZE, BY MUMPS & RUBELLA, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 42. GLOBAL VACCINES MARKET SIZE, BY MUMPS & RUBELLA, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 43. GLOBAL VACCINES MARKET SIZE, BY PNEUMOCOCCAL DISEASE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 44. GLOBAL VACCINES MARKET SIZE, BY PNEUMOCOCCAL DISEASE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 45. GLOBAL VACCINES MARKET SIZE, BY POLIO, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 46. GLOBAL VACCINES MARKET SIZE, BY POLIO, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 47. GLOBAL VACCINES MARKET SIZE, BY ROTAVIRUS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 48. GLOBAL VACCINES MARKET SIZE, BY ROTAVIRUS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 49. GLOBAL VACCINES MARKET SIZE, BY VARICELLA, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 50. GLOBAL VACCINES MARKET SIZE, BY VARICELLA, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 51. GLOBAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 52. GLOBAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 53. GLOBAL VACCINES MARKET SIZE, BY INTRAMUSCULAR & SUBCUTANEOUS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 54. GLOBAL VACCINES MARKET SIZE, BY INTRAMUSCULAR & SUBCUTANEOUS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 55. GLOBAL VACCINES MARKET SIZE, BY ORAL, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 56. GLOBAL VACCINES MARKET SIZE, BY ORAL, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 57. GLOBAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 58. GLOBAL VACCINES MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 59. GLOBAL VACCINES MARKET SIZE, BY ADULTS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 60. GLOBAL VACCINES MARKET SIZE, BY ADULTS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 61. GLOBAL VACCINES MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 62. GLOBAL VACCINES MARKET SIZE, BY PEDIATRIC, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 63. AMERICAS VACCINES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 64. AMERICAS VACCINES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 65. AMERICAS VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2023 (USD MILLION)
  • TABLE 66. AMERICAS VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2024-2030 (USD MILLION)
  • TABLE 67. AMERICAS VACCINES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 68. AMERICAS VACCINES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 69. AMERICAS VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 70. AMERICAS VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 71. AMERICAS VACCINES MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 72. AMERICAS VACCINES MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 73. AMERICAS VACCINES MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 74. AMERICAS VACCINES MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 75. ARGENTINA VACCINES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 76. ARGENTINA VACCINES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 77. ARGENTINA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2023 (USD MILLION)
  • TABLE 78. ARGENTINA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2024-2030 (USD MILLION)
  • TABLE 79. ARGENTINA VACCINES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 80. ARGENTINA VACCINES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 81. ARGENTINA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 82. ARGENTINA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 83. ARGENTINA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 84. ARGENTINA VACCINES MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 85. BRAZIL VACCINES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 86. BRAZIL VACCINES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 87. BRAZIL VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2023 (USD MILLION)
  • TABLE 88. BRAZIL VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2024-2030 (USD MILLION)
  • TABLE 89. BRAZIL VACCINES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 90. BRAZIL VACCINES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 91. BRAZIL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 92. BRAZIL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 93. BRAZIL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 94. BRAZIL VACCINES MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 95. CANADA VACCINES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 96. CANADA VACCINES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 97. CANADA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2023 (USD MILLION)
  • TABLE 98. CANADA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2024-2030 (USD MILLION)
  • TABLE 99. CANADA VACCINES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 100. CANADA VACCINES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 101. CANADA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 102. CANADA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 103. CANADA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 104. CANADA VACCINES MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 105. MEXICO VACCINES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 106. MEXICO VACCINES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 107. MEXICO VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2023 (USD MILLION)
  • TABLE 108. MEXICO VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2024-2030 (USD MILLION)
  • TABLE 109. MEXICO VACCINES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 110. MEXICO VACCINES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 111. MEXICO VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 112. MEXICO VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 113. MEXICO VACCINES MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 114. MEXICO VACCINES MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 115. UNITED STATES VACCINES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 116. UNITED STATES VACCINES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 117. UNITED STATES VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2023 (USD MILLION)
  • TABLE 118. UNITED STATES VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2024-2030 (USD MILLION)
  • TABLE 119. UNITED STATES VACCINES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 120. UNITED STATES VACCINES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 121. UNITED STATES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 122. UNITED STATES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 123. UNITED STATES VACCINES MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 124. UNITED STATES VACCINES MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 125. UNITED STATES VACCINES MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 126. UNITED STATES VACCINES MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC VACCINES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC VACCINES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2023 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2024-2030 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC VACCINES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC VACCINES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC VACCINES MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC VACCINES MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC VACCINES MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC VACCINES MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 139. AUSTRALIA VACCINES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 140. AUSTRALIA VACCINES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 141. AUSTRALIA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2023 (USD MILLION)
  • TABLE 142. AUSTRALIA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2024-2030 (USD MILLION)
  • TABLE 143. AUSTRALIA VACCINES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 144. AUSTRALIA VACCINES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 145. AUSTRALIA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 146. AUSTRALIA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 147. AUSTRALIA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 148. AUSTRALIA VACCINES MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 149. CHINA VACCINES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 150. CHINA VACCINES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 151. CHINA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2023 (USD MILLION)
  • TABLE 152. CHINA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2024-2030 (USD MILLION)
  • TABLE 153. CHINA VACCINES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 154. CHINA VACCINES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 155. CHINA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 156. CHINA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 157. CHINA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 158. CHINA VACCINES MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 159. INDIA VACCINES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 160. INDIA VACCINES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 161. INDIA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2023 (USD MILLION)
  • TABLE 162. INDIA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2024-2030 (USD MILLION)
  • TABLE 163. INDIA VACCINES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 164. INDIA VACCINES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 165. INDIA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 166. INDIA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 167. INDIA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 168. INDIA VACCINES MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 169. INDONESIA VACCINES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 170. INDONESIA VACCINES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 171. INDONESIA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2023 (USD MILLION)
  • TABLE 172. INDONESIA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2024-2030 (USD MILLION)
  • TABLE 173. INDONESIA VACCINES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 174. INDONESIA VACCINES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 175. INDONESIA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 176. INDONESIA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 177. INDONESIA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 178. INDONESIA VACCINES MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 179. JAPAN VACCINES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 180. JAPAN VACCINES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 181. JAPAN VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2023 (USD MILLION)
  • TABLE 182. JAPAN VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2024-2030 (USD MILLION)
  • TABLE 183. JAPAN VACCINES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 184. JAPAN VACCINES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 185. JAPAN VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 186. JAPAN VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 187. JAPAN VACCINES MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 188. JAPAN VACCINES MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 189. MALAYSIA VACCINES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 190. MALAYSIA VACCINES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 191. MALAYSIA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2023 (USD MILLION)
  • TABLE 192. MALAYSIA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2024-2030 (USD MILLION)
  • TABLE 193. MALAYSIA VACCINES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 194. MALAYSIA VACCINES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 195. MALAYSIA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 196. MALAYSIA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 197. MALAYSIA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 198. MALAYSIA VACCINES MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 199. PHILIPPINES VACCINES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 200. PHILIPPINES VACCINES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 201. PHILIPPINES VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2023 (USD MILLION)
  • TABLE 202. PHILIPPINES VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2024-2030 (USD MILLION)
  • TABLE 203. PHILIPPINES VACCINES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 204. PHILIPPINES VACCINES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 205. PHILIPPINES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 206. PHILIPPINES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 207. PHILIPPINES VACCINES MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 208. PHILIPPINES VACCINES MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 209. SINGAPORE VACCINES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 210. SINGAPORE VACCINES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 211. SINGAPORE VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2023 (USD MILLION)
  • TABLE 212. SINGAPORE VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2024-2030 (USD MILLION)
  • TABLE 213. SINGAPORE VACCINES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 214. SINGAPORE VACCINES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 215. SINGAPORE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 216. SINGAPORE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 217. SINGAPORE VACCINES MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 218. SINGAPORE VACCINES MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 219. SOUTH KOREA VACCINES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 220. SOUTH KOREA VACCINES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 221. SOUTH KOREA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2023 (USD MILLION)
  • TABLE 222. SOUTH KOREA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2024-2030 (USD MILLION)
  • TABLE 223. SOUTH KOREA VACCINES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 224. SOUTH KOREA VACCINES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 225. SOUTH KOREA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 226. SOUTH KOREA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 227. SOUTH KOREA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 228. SOUTH KOREA VACCINES MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 229. TAIWAN VACCINES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 230. TAIWAN VACCINES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 231. TAIWAN VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2023 (USD MILLION)
  • TABLE 232. TAIWAN VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2024-2030 (USD MILLION)
  • TABLE 233. TAIWAN VACCINES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 234. TAIWAN VACCINES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 235. TAIWAN VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 236. TAIWAN VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 237. TAIWAN VACCINES MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 238. TAIWAN VACCINES MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 239. THAILAND VACCINES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 240. THAILAND VACCINES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 241. THAILAND VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2023 (USD MILLION)
  • TABLE 242. THAILAND VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2024-2030 (USD MILLION)
  • TABLE 243. THAILAND VACCINES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 244. THAILAND VACCINES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 245. THAILAND VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 246. THAILAND VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 247. THAILAND VACCINES MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 248. THAILAND VACCINES MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 249. VIETNAM VACCINES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 250. VIETNAM VACCINES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 251. VIETNAM VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2023 (USD MILLION)
  • TABLE 252. VIETNAM VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2024-2030 (USD MILLION)
  • TABLE 253. VIETNAM VACCINES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 254. VIETNAM VACCINES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 255. VIETNAM VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 256. VIETNAM VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 257. VIETNAM VACCINES MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 258. VIETNAM VACCINES MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 259. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 260. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 261. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2023 (USD MILLION)
  • TABLE 262. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2024-2030 (USD MILLION)
  • TABLE 263. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 264. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 265. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 266. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 267. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 268. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 269. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 270. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 271. DENMARK VACCINES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 272. DENMARK VACCINES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 273. DENMARK VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2023 (USD MILLION)
  • TABLE 274. DENMARK VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2024-2030 (USD MILLION)
  • TABLE 275. DENMARK VACCINES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 276. DENMARK VACCINES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 277. DENMARK VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 278. DENMARK VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 279. DENMARK VACCINES MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 280. DENMARK VACCINES MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 281. EGYPT VACCINES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 282. EGYPT VACCINES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 283. EGYPT VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2023 (USD MILLION)
  • TABLE 284. EGYPT VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2024-2030 (USD MILLION)
  • TABLE 285. EGYPT VACCINES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 286. EGYPT VACCINES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 287. EGYPT VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 288. EGYPT VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 289. EGYPT VACCINES MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 290. EGYPT VACCINES MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 291. FINLAND VACCINES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 292. FINLAND VACCINES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 293. FINLAND VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2023 (USD MILLION)
  • TABLE 294. FINLAND VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2024-2030 (USD MILLION)
  • TABLE 295. FINLAND VACCINES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 296. FINLAND VACCINES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 297. FINLAND VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 298. FINLAND VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 299. FINLAND VACCINES MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 300. FINLAND VACCINES MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 301. FRANCE VACCINES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 302. FRANCE VACCINES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 303. FRANCE VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2023 (USD MILLION)
  • TABLE 304. FRANCE VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2024-2030 (USD MILLION)
  • TABLE 305. FRANCE VACCINES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 306. FRANCE VACCINES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 307. FRANCE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 308. FRANCE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 309. FRANCE VACCINES MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 310. FRANCE VACCINES MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 311. GERMANY VACCINES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 312. GERMANY VACCINES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 313. GERMANY VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2023 (USD MILLION)
  • TABLE 314. GERMANY VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2024-2030 (USD MILLION)
  • TABLE 315. GERMANY VACCINES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 316. GERMANY VACCINES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 317. GERMANY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 318. GERMANY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 319. GERMANY VACCINES MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 320. GERMANY VACCINES MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 321. ISRAEL VACCINES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 322. ISRAEL VACCINES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 323. ISRAEL VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2023 (USD MILLION)
  • TABLE 324. ISRAEL VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2024-2030 (USD MILLION)
  • TABLE 325. ISRAEL VACCINES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 326. ISRAEL VACCINES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 327. ISRAEL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 328. ISRAEL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 329. ISRAEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 330. ISRAEL VACCINES MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 331. ITALY VACCINES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 332. ITALY VACCINES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 333. ITALY VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2023 (USD MILLION)
  • TABLE 334. ITALY VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2024-2030 (USD MILLION)
  • TABLE 335. ITALY VACCINES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 336. ITALY VACCINES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 337. ITALY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 338. ITALY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 339. ITALY VACCINES MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 340. ITALY VACCINES MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 341. NETHERLANDS VACCINES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 342. NETHERLANDS VACCINES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 343. NETHERLANDS VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2023 (USD MILLION)
  • TABLE 344. NETHERLANDS VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2024-2030 (USD MILLION)
  • TABLE 345. NETHERLANDS VACCINES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 346. NETHERLANDS VACCINES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 347. NETHERLANDS VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 348. NETHERLANDS VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 349. NETHERLANDS VACCINES MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 350. NETHERLANDS VACCINES MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 351. NIGERIA VACCINES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 352. NIGERIA VACCINES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 353. NIGERIA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2023 (USD MILLION)
  • TABLE 354. NIGERIA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2024-2030 (USD MILLION)
  • TABLE 355. NIGERIA VACCINES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 356. NIGERIA VACCINES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 357. NIGERIA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 358. NIGERIA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 359. NIGERIA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 360. NIGERIA VACCINES MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 361. NORWAY VACCINES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 362. NORWAY VACCINES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 363. NORWAY VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2023 (USD MILLION)
  • TABLE 364. NORWAY VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2024-2030 (USD MILLION)
  • TABLE 365. NORWAY VACCINES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 366. NORWAY VACCINES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 367. NORWAY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 368. NORWAY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 369. NORWAY VACCINES MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 370. NORWAY VACCINES MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 371. POLAND VACCINES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 372. POLAND VACCINES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 373. POLAND VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2023 (USD MILLION)
  • TABLE 374. POLAND VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2024-2030 (USD MILLION)
  • TABLE 375. POLAND VACCINES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 376. POLAND VACCINES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 377. POLAND VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 378. POLAND VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 379. POLAND VACCINES MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 380. POLAND VACCINES MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 381. QATAR VACCINES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 382. QATAR VACCINES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 383. QATAR VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2023 (USD MILLION)
  • TABLE 384. QATAR VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2024-2030 (USD MILLION)
  • TABLE 385. QATAR VACCINES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 386. QATAR VACCINES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 387. QATAR VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 388. QATAR VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 389. QATAR VACCINES MARKET SIZE, BY AGE GROUP, 2018-202